Abstract: A culture medium is disclosed which comprises STAT3 activator, an ERK1/2 inhibitor and an Axin stabilizer, and optionally also a PKC inhibitor. Cell cultures comprising same and uses thereof are also disclosed.

Abstract: A method of treating a psychiatric disorder in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an N-methyl-D-aspartate (NMDA) receptor antagonist and a therapeutically effective amount of a KCNQ channel activator. Pharmaceutical compositions comprising an NMDA receptor antagonist and a KCNQ channel activator are also disclosed.

Abstract: Given an input image, an image enhancement task, and no external examples available to train on, an Image-Specific Deep Network is constructed tailored to solve the task for this specific image. Since there are no external examples available to train on, the network is trained on examples extracted directly from the input image itself. The current solution solves the problem of Super-Resolution (SR), whereas the framework is more general and is not restricted to SR.

Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.

Abstract: This invention is directed to an aromatic material based free-standing film, a hybrid of organic crystalline materials and inorganic carbon nanomaterials, process of preparation and uses thereof. The film, which comprises a fibrous organic nanocrystals of an aromatic material, is mechanically and thermally stable. This film is optionally reinforced by hybridization with a reinforcement material, such as carbon nanotube, carbon material, a polysaccharide, a nanoclay a metal, metal alloy, or an organic polymer. The hybrid film of organic nanocrystals and carbon nanotubes (ONC/CNT) has high conductivity and high thermal stability. The films or hybrids of this invention are used as microfiltration membranes for various materials, in electrodes or perovskite solar cells.

Abstract: A method for recovery of platinum group metals from a spent catalyst is described. The method includes crushing the spent catalyst to obtain a catalyst particulate material including particles having a predetermined grain size. The method includes subjecting the catalyst particulate material to a chlorinating treatment in the reaction zone at a predetermined temperature for a predetermined time period by putting the catalyst particulate material in contact with the chlorine containing gas. The method also includes applying an electromagnetic field to the chlorine-containing gas in the reaction zone to provide ionization of chlorine; thereby to cause a chemical reaction between platinum group metals and chlorine ions and provide a volatile platinum group metal-containing chloride product in the reaction zone. Following this, the volatile platinum group metal-containing chloride product is cooled to convert the product into solid phase platinum group metal-containing materials.

Abstract: An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

Abstract: A method of generating an image of a sample is provided. The method comprises providing a plurality of photon detectors, scanning the sample with an excitation beam over a predetermined time period, the detectors receiving photons emitted by the sample due to the excitation during the time period. A plurality of intensity images associated with each of the detectors are generated, each being proportional to the mean number of photons detected per unit time. A plurality of correlation images associated with each combination of two of the detectors are generated, each of the correlation images being proportional to the variance of the distribution of detected photons per unit time. The image of the sample is generated using joint sparse recovery from the plurality of intensity and correlation images, wherein the intensity and correlation images have common support.

Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Abstract: Agents binding modified antigen dependent peptides and use of same are provided. Accordingly, there is provided an agent capable of specifically binding an MHC presented peptide comprising a post translational modification (PTM), wherein the agent does not bind a peptide having the same amino acid sequence as said peptide but does not comprise said modification. Also provided are polynucleotides encoding the agent, cells expressing same and methods of use thereof. Also provided is a computer implemented method for generating a dataset of PTM on MHC bound peptides.

Abstract: Methods and devices for ex-utero mouse embryonic development are provided. Accordingly, there is provided a method of ex-utero culturing a mouse embryo at a zygote stage under conditions that allow developments of the embryo to organogenesis or any developmental stage therein-between. Also provided a fetal incubation system, and methods of using same.

Abstract: A composition of matter comprising a synthetic miR-135 molecule comprising a nucleic acid sequence of a miR-135b as set forth in SEQ ID NO: 37, and a complementary strand as set forth in SEQ ID NO: 40 is disclosed. A conjugate comprising a composition of matter comprising a synthetic miR-135 molecule and a cell-targeting moiety is also disclosed.

Abstract: A recombinant system for improving genome editing via homologous recombination is disclosed. The system comprising a first nucleic acid sequence encoding a DNA editing agent having a double strand DNA cutting activity and a second nucleic acid sequence encoding a polypeptide capable of increasing homologous recombination in a target cell.

Abstract: A vaccine comprising a pharmaceutically acceptable carrier and bacteria which presents at least one cancer-associated antigen is disclosed. The bacteria are not genetically modified to express the at least one cancer-associated antigen. Uses thereof are also disclosed.

Abstract: A vaccine comprising tumor-homing bacteria which are genetically modified to express at least one cancer-associated antigen and a pharmaceutically acceptable carrier is disclosed. Uses thereof are also disclosed.

Abstract: Particles having an ACE2 targeting moiety attached to an outer surface thereof are disclosed herein. The ACE2 targeting moiety comprises a polypeptide comprising an amino acid sequence of SARS CoV-2 receptor-binding domain (RBD), wherein said amino acid sequence comprises a modification at position 358 and at least two additional modifications at two positions selected from the group consisting of 484, 498 and 501. Uses of the particles for treatment and diagnosis of diseases are also disclosed.

Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.